Who won: Medical genetic testing kits

About this contract

The All Wales Medical Genomics Service (AWMGS) has routinely utilised Multiplex Ligation-Dependent Probe Amplification (MLPA) as a diagnostic tool for identifying Copy Number Variations (CNVs)—including deletions and duplications—across a range of genetic disorders. This testing supports clinical decision-making and patient treatment strategies.MLPA technology involves the use of oligonucleotide probe pairs that hybridise to specific DNA sequences within target genes. When both probes bind adjacently at a site of interest, they are ligated and subsequently amplified via Polymerase Chain Reaction (PCR). The amplified DNA fragments are then separated by capillary electrophoresis and analysed to detect CNVs.Since its inception, AWMGS has exclusively sourced MLPA probes and reagents from MRC Holland, a Netherlands-based supplier recognised for its specialised products in molecular diagnostics.

Who won contracts like this

• ✓Answer against the marking scheme, not the question text — Cardiff and Vale University Health Board scores each response, so map your evidence to the published criteria and weightings.
• ✓Lead with evidenced capability and social value — for public sector work these usually outweigh price.
• ✓Show recent, comparable delivery: name similar public sector contracts you've delivered for public bodies, with measurable outcomes.
• ✓This one's been awarded — but Cardiff and Vale University Health Board retenders on a cycle. Get matched the day the next one lands and start your draft early.

BidWriter drafts your responses from your company profile, scores them against the marking scheme, and tracks your whole pipeline. Free to start — no card needed.

Related resources